[Combination chemotherapy of mitomycin C and cytosine arabinoside in superficial bladder tumors. 1. Evaluation of intravesical infusion therapy].
A combined chemotherapy of Mitomycin C (20-30 mg) and Cytosine Arabinoside (200 mg) was given intravesical by to 37 patients with superficial bladder tumor. The antitumor effect of the therapy was evaluated as follows. 1) The results were: remarkably effective in 12 cases (32.5%); effective in, 14 cases (37.8%); non-effective in 11 cases (29.7%), with overall rate of 70.3%. 2) The antitumor effect tended to be evident in multiple tumors, small tumors, and tumors of low malignancy. 3) Side effects were found in 35.1% of the cases including 24.3% of bladder irritating symptom. 4) The follow-up period ranged from 12 to 60 months with an average of 36.6 months. Recurrence rate was 27.0%. There was a tendency that recurrence occurred more frequently in cases of multiple tumors and small tumors than in other cases.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D001743:Urinary Bladder; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014546:Urinary Catheterization
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D003561:Cytarabine; D016685:Mitomycin